Results 31 to 40 of about 4,786,268 (341)

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. [PDF]

, 2020
Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti-HCMV human monoclonal antibodies (LJP538 and LJP539) that bind to and inhibit ...
Akard, Luke, Chemaly, Roy, Christoph, Sandra, Gerbitz, Armin, Hiemenz, John, Holler, Ernst, Hwang, William YK, Jang, Junho, Koh, Liang Piu, Lee, Dong-Gun, Logan, Aaron C, Long, Gwynn, Maertens, Johan, Mielke, Stephan, Pertel, Peter, Ramachandra, Sangana, Segal, Florencia, Smith, Kristin, Tang, Jih-Luh, Wang, Po-Nan, Winkler, Julia, Yeh, Su-Peng, Yeo, Adeline   +22 more
core   +3 more sources

How to improve the outcomes of elderly acute myeloid leukemia patients through allogeneic hematopoietic stem cell transplantation

Frontiers in Immunology, 2023
In recent years, with the gradual advancement of haploidentical transplantation technology, the availability of donors has increased significantly, along with the widespread use of reduced-intensity conditioning and the improvement of nursing techniques,
Shan Jiang, Han Yan, Xuan Lu, Ruowen Wei, Haoran Chen, Ao Zhang, Wei Shi, Linghui Xia   +7 more
doaj   +1 more source

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia. [PDF]

, 2017
We developed a haploidentical transplantation protocol with post-transplant cyclophosphamide (CY) for in vivo T-cell depletion (TCD) using a novel adapted-dosing schedule (25 mg/kg on days +3 and +4) for Fanconi anemia (FA).
Bonfim, C, Burroughs, L, Kiem, H-P, Pasquini, R, Sandmaier, BM, Storb, R, Thakar, MS, Walters, MC, Woolfrey, A   +8 more
core   +2 more sources

Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France

Haematologica, 2014
Double cord blood transplantation extends the use of cord blood to adults for whom a single unit is not available, but the procedure is limited by its cost.
Myriam Labopin, Annalisa Ruggeri, Norbert Claude Gorin, Eliane Gluckman, Didier Blaise, Lionel Mannone, Noel Milpied, Ibrahim Yakoub-Agha, Eric Deconinck, Mauricette Michallet, Nathalie Fegueux, Gerard Socié, Stephanie Nguyen, Jean Yves Cahn, Thierry de Revel, Federico Garnier, Catherine Faucher, Namik Taright, Chantal Kenzey, Fernanda Volt, Dominique Bertrand, Mohamad Mohty, Vanderson Rocha   +22 more
doaj   +1 more source

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse [PDF]

, 2012
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion.
Beyer, Jörg, Blau, Igor Wolfgang, Burmeister, Thomas, Friedrichs, Birte, Lachmann, Nils, Lohm, Gunnar, Marschalek, Rolf, Meyer, Claus, Molkentin, Mara, Schwartz, Stefan, Tietze-Bürger, Carola, Uharek, Lutz   +11 more
core   +1 more source

Syngeneic peripheral blood stem cell transplantation with immunosuppression for hepatitis-associated severe aplastic anemia

Turkish Journal of Hematology, 2010
Hepatitis-associated aplastic anemia occurs in up to 10% of all aplastic anemia cases. Syngeneic bone marrow transplantation is rare in patients with severe aplastic anemia and usually requires pre-transplant conditioning to provide engraftment.
Aleksandar Savic, Bela Balint, Ivana Urosevic, Nebojsa Rajic, Milena Todorovic, Ivanka Percic, Stevan Popovic   +6 more
doaj   +3 more sources

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019

Haematologica, 2019
Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic ...
Donal P. McLornan, Ibrahim Yakoub-Agha, Marie Robin, Yves Chalandon, Claire N. Harrison, Nicolaus Kroger   +5 more
doaj   +1 more source

Is There (Still) a Place for Sequential Conditioning?

Current Oncology
There is still an unmet need for the treatment of high-risk hematological malignancies. To date, allogeneic stem cell transplantation remains the only chance of cure.
Boris Bours, Stavroula Masouridi-Levrat
doaj   +1 more source

Posttransplantation Lymphoproliferative Disease Treated by Retransplantation

Case Reports in Immunology, 2020
Epstein–Barr virus- (EBV-) induced posttransplantation lymphoproliferative disease (PTLD) is a life-threatening complication following allogeneic stem cell transplantation. The main risk factor is anti-thymocyte globulin (ATG).
Ingerid Weum Abrahamsen, Bjørn Christer Grønvold, Else Marit Inderberg, Nadia Mensali, Jonas Mattsson, Tobias Gedde-Dahl   +5 more
doaj   +1 more source

A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest

Cardio-Oncology, 2020
High dose melphalan is commonly used as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. There are reports of adverse cardiac events with melphalan manifested by supraventricular tachycardia and atrial fibrillation ...
Liang-Liang Ma, Ying Liu, Si-Xun Jia, Hai-Chen Lv, Mei-Yun Fang, Yun-Long Xia   +5 more
doaj   +1 more source